Captor Therapeutics S.A. Logo

Captor Therapeutics S.A.

Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.

CTX | WAR

Overview

Corporate Details

ISIN(s):
PLCPTRT00014 (+1 more)
LEI:
259400JHH1S2I2S4O735
Country:
Poland
Address:
Wrocław Duńska 11, 54-427 Wrocław
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Captor Therapeutics S.A. is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel therapeutics using Targeted Protein Degradation (TPD) technology. The company focuses on creating breakthrough, first-in-class treatments for high unmet medical needs, particularly in oncology and autoimmune diseases. Its core is the proprietary Optigrade™ drug discovery platform, which leverages multidisciplinary expertise in protein engineering, structural biology, and molecular modelling. This integrated approach enables the company to address previously "undruggable" molecular targets, accelerating the development of drug candidates with the potential to significantly impact patient outcomes.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-27 16:06
Director's Dealing
załącznik
Polish 4.5 KB
2025-11-27 16:06
Director's Dealing
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Conte…
Polish 484 bytes
2025-11-27 14:09
Director's Dealing
załącznik
Polish 4.4 KB
2025-11-27 14:09
Director's Dealing
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Conte…
Polish 657 bytes
2025-11-25 10:23
Director's Dealing
załącznik
Polish 5.1 KB
2025-11-25 10:23
Director's Dealing
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Conte…
Polish 713 bytes
2025-11-20 17:07
Regulatory Filings
Śródroczne skrócone skonsolidowane oraz jednostkowe sprawozdanie finansowe spor…
Polish 1.1 MB
2025-11-20 17:07
Regulatory Filings
Rozszerzony skonsolidowany raport kwartalny Grupy Kapitałowej Captor Therapeuti…
Polish 1.1 MB
2025-11-18 19:12
Regulatory Filings
Porozumienie o współpracy z Centrum Onkologicznym MD Anderson przy Uniwersyteci…
Polish 2.8 KB
2025-11-18 18:56
M&A Activity
Zawarcie umowy o współpracy badawczej i opcji licencyjnej z amerykańską publicz…
Polish 1.7 KB
2025-11-14 15:06
Legal Proceedings Report
Złożenie do Agencji Badań Medycznych wniosku o zakończenie realizacji projektu …
Polish 899 bytes
2025-10-27 13:41
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających na Nadzwyczajnym Walnym Zgromadzeniu Spółki …
Polish 2.0 KB
2025-10-24 18:29
Regulatory Filings
Zawarcie umowy z Europejską Radą ds. Innowacji i Agencją Wykonawczą ds. MŚP (EI…
Polish 1.3 KB
2025-10-22 17:51
AGM Information
treść uchwał
Polish 465.8 KB
2025-10-22 17:51
AGM Information
Treść uchwał podjętych przez Nadzwyczajne Walne Zgromadzenie 22 października 20…
Polish 1.2 KB

Automate Your Workflow. Get a real-time feed of all Captor Therapeutics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Captor Therapeutics S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Captor Therapeutics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain
IKM
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapies for oncology & ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation platform for designing and optimizing biologic therapeutics.
United States of America
ABSI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland
ACHI
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America
ADAG

Talk to a Data Expert

Have a question? We'll get back to you promptly.